sofosbuvir + ritonavir + darunavir + emtricitabine + tenofovir disoproxil fumarate

A combination of five **antiviral drugs**: sofosbuvir (an HCV nucleotide analog NS5B polymerase inhibitor), ritonavir (a pharmacokinetic enhancer/boosting agent and HIV protease inhibitor), darunavir (an HIV protease inhibitor), emtricitabine (an HIV nucleoside reverse transcriptase inhibitor), and tenofovir disoproxil fumarate (a prodrug of the HIV nucleotide reverse transcriptase inhibitor tenofovir). This combination would theoretically provide broad-spectrum antiviral coverage targeting both **HIV-1** (with darunavir, ritonavir, emtricitabine, and tenofovir) and **hepatitis C virus (HCV)** (with sofosbuvir), but it is not an approved or standard regimen. All components are **small molecules** approved individually or in other fixed-dose combinations for HIV and/or HCV infection. The simultaneous use of all these agents together is not a standard practice and may have significant drug-drug interaction risks, particularly due to overlapping toxicity and pharmacokinetic boosting with ritonavir. There is evidence of interactions and a need for dose consideration if combining these agents[2][4]. No branded or fixed-dose combination with these five agents exists; this appears to be a nonstandard, hypothetical combination regimen.